Methotrexate

Clinics in Dermatology

Volumn 15, Issue 5, 1997, Pages 781-797

  Said, Samireh ^a   Jeffes, Edward W B ^b   Weinstein, Gerald D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMINOPTERIN; ANTIBIOTIC AGENT; BARBITURIC ACID DERIVATIVE; COLCHICINE; COLLAGEN; CREATININE; DIHYDROFOLATE REDUCTASE; DIPYRIDAMOLE; DNA; FOLIC ACID DERIVATIVE; HYDROCORTISONE; LIVER ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PLASMA PROTEIN; PROBENECID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RETINOID; RNA; THYMIDINE; TRANQUILIZER;

ANAPHYLAXIS; BLOOD TOXICITY; BONE DISEASE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; GASTROINTESTINAL SYMPTOM; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER BIOPSY; LIVER TOXICITY; LUNG TOXICITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0030827145     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00014-X     Document Type: Article

References (127)

1. Farber S, Diamond LK, Mercer RD. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminoptheroylglutamic acid (aminopterin). N Engl J Med 1948;238:787-9.
2. Gubner R. Effect of "Aminopterin" on epithelial tissues. Arch Dermatol Syphilol 1951;64:688-99.
3. Rees R, Bennett J. Methotrexate vs aminopterin for psoriasis. Arch Dermatol 1961;83:970-2.
4. Van Scott E, Auerbach R, Weinstein GD, et al. Parenteral methotrexate in psoriasis. Arch Dermatol 1964;89:550-6.
5. Rees R, Bennett J, Maibach HI, et al. Aminopterin for psoriasis. Arch Dermatol 1955;72:133-43.
6. Rees R, Bennett J. Further observations on aminopterin for psoriasis. J Invest Dermatol 1959;32:61-6.
7. Roenigk H, Fowler-Bergfeld W, Curtis GH, et al. Methotrexate for psoriasis in weekly oral doses. Arch Dermatol 1969;99:86-93.
8. Nyfors A, Brodthagen H. Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 1970;140:345~55.
9. Weinstein G, Frost P. Methotrexate in psoriasis: A new therapeutic schedule. Arch Dermatol 1971;103:33-8.
10. Van Dooren-Greebe RJ, Kuijpers AL, Termorshuizen F, et al. Interruption of long-term methotrexate treatment in psoriasis. Evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate. Acta Derm Venereol (Stockh) 1995;75:393-6.
11. Jeffes EWB, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995;104:183-8.
12. Jeffes EWB, Lee G, Said S, et al. Elevated numbers of proliferating mononuclear cells in the peripheral blood of psoriatic patients correlate with disease severity. J Invest Dermatol 1995;105:733-8.
13. Weinstein GD, Jeffes E, McCullough JL. Cytotoxic and immunologie effects of methotrexate in psoriasis. J Invest Dermatol 1990;95:49S-52S.
14. Cronstein B. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992;16:411-23.
15. Weinstein G, Goldfaden G, Frost P. Methotrexate: Mechanism of action on DNA synthesis in psoriasis. Arch Dermatol 1971;104:236-43.
16. Weinstein G, Velasco J. Selective action of methotrexate on psoriatic epidermal cells. J Invest Dermatol 1972;59:121-7.
17. Newburger A, Weinstein G, McCullough JL. Biological and biochemical actions of methotrexate in psoriasis. J Invest Dermatol 1978;70:183-6,
18. Halprin D, Fukui K, Ohkawara A. Blood levels of methotrexate and the treatment of psoriasis. Arch Dermatol 1971;103:243-9.
19. Kamel R, Al-Hakiem M, et al. Pharmacokinetics of small doses of methotrexate in patients with psoriasis. Acta Derm Venerol (Stockh) 1988;68:267-70.
20. McCullough J, Snyder D, Weinstein G, et al. Factors affecting human percutaneous penetration of methotrexate and its analogues in vitro: J Invest Dermatol 1976;67:26-30.
21. Weinstein G, McCullough J. Cytokinetics and chemotherapy of psoriasis. J Invest Dermatol 1976;67:26-30.
22. McCullough J, Weinstein G, Hynes J. Pharmacologic aspects of screening new folic acid antagonists for topical use in psoriasis. In: Fargber E, Cox A, editors. Proceedings of the Second International Symposium for Psoriasis. New York: Standford Press, 1977:422-6.
23. McCullough J, Weinstein G. The role of cell kinetics in the chemotherapy of hyperproliferarive skin diseases: A review. J Pharmacol Ther 1979;6:601-15.
24. Weinstein G, McCullough J, Eaglestein W, et al. A clinical screening program for topical chemotherapeutic drugs in psoriasis. Arch Dermatol 1981;117:388-93.
25. Lowe N, Stoughton R, McCough J, et al. A clinical screening program for topical chemotherapeutic drugs in psoriasis. Arch Dermatol 1981;117:388-93.
26. Ball M, McCoullough J, Weinstein G. Percutaneous absorption of methotrexate: Effect on epidermal DNA synthesis in hairless mice. J Invest Dermatol 1982;79:7-10.
27. Bjerring P, Beck H, Zachariae H, et al. Topical treatment of psoriatic skin with methotrexate cream: A dinical, pharmokinetic, and histological study. Acta Derm Venereol (Stockh) 1986;66:515-9.
28. Taylor I, Tattersall M. Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry. Cancer Res 1981;41:1549-58.
29. Hryniuk W. The mechanism of action of methotrexate in cultured L5278Y leukemia cells. Cancer Res 1975;35:1085-92.
30. Huffman D, Wan S, Azarnoff DL, et al. Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973;14:572-9.
31. Roenigk H, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: Revised guidelines. J Am Acad Dermatol 1988;19:145-56.
32. Kumar B, Dhar S, Handa S, et al. Methotrexate in childhood psoriasis. Pediatr Dermatol 1994;11:271-3.
33. Maurer TA, Zackheim, Tuffanelli L, et al. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 19941:372-5.
34. Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol 1987;123:1622-32.
35. Winchester R, Bernstein DH, Fischer HD, et al. The cooccurence of Reiter's syndrome and acquired immunodeficiency. Ann Intern Med 1987;106:19-26.
36. Auerbach R. Psoriasis symposium. Methotrexate. Semin Dermatol 1992;11(4S1):23-9.
37. Whiting-O'Keffe Q, Fye K, Sack KD. Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am J Med 1991;90:711-6.
38. Roenigk H, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: Updated guidelines (unpublished).
39. Weinstein G, Roenigk H, Maibach H, et al. Psoriasisliver-methotrexate interactions. Arch Dermatol 1973;108:36-42.
40. Tobias H, Auerbach R. Hepatotoxicity of long-term methotrexate therapy for psoriasis. Arch Intern Med 1973;132:391-6.
41. Nyfors A, Poulsen H. Liver biopsies from psoriatics related to methotrexate therapy. Two findings before and after methotrexate therapy in 88 patients. A blind study. Acta Pathologica et Microbiologica Scandinavica. 1976;84:262-70.
42. Reese LT, Grisham JW, Aach RD, et al. Effects of methotrexate on the liver in psoriasis. J Invest Dermatol 1974;62:597-602.
43. O'Conner GT, Olmstead EM, Zug K, et al. Detection of hepatotoxicity associated with methotrexate therapy for psoriasis. Arch Dermatol 1989;125:1209-17.
44. Frei A, Zimmerman A, Wiegand K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 1984;4:830-34.
45. Zachariae H, Aslam HM, Bjerring P, et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991;25:50-53.
46. Mitchell D, Smith A, Rowan B, et al. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990;122:1-7.
47. Fairris G, Dewhurst A, White JE, et al. Methotrexate dosage in patients aged over 50 with psoriasis. Br Med J 1989;298:801-2.
48. Peckham P, Weinstein G, McCullough JL. The treatment of severe psoriasis. Arch Dermatol 1987;123:1303-7.
49. Jeffes EWB, Weinstein G. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin 1995;13:4:875-90.
50. Weinstein G, White G. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993;28:454-9.
51. Zachheim H. Subcutaneous administration of methotrexate. J Am Acad Dermatol 1992;26:1008.
52. Colsky J, Greenspan EM, Warren TN. Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonists. Arch Pathol 1955;59:198-206.
53. Nyfors A. Liver biopsies form psoriatics related to methotrexate therapy. AMPIS 1977;85:511-8.
54. Zachariae H, Kragballe K, Sogaard H. Methotrexate-induced liver cirrhosis: studies including serial liver biopsies during continued treatment. Br J Dermatol 1980;102:407-12.
55. Gilbert S, Klintmalm G, Menter A, et al. MTX-induced cirrhosis requiring transplantation in three patients with psoriasis: A word of caution in light of the expanding use of this "steroid-sparing" agent. Arch Intern Med 1990;150:889-91.
56. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
57. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991;25:306-18.
58. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: How safe is it? Ann Intern Med 1993;118:150-3.
59. Piccinino F, Sagnelli G, Giusti G. Complications following percutaneous liver biopsy: a multicenter retrospective study on 68,276 biopsies. J Hepatol 1986;2:165-73.
60. Roenigk H, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised. J Am Acad Dermatol 1982;6:145-55.
61. Bertino J. Rescue techniques in cancer chemotherapy: Use of leucovorin rescue agents after methotrexate treatments. Semin Oncol 1977;4:203-16.
62. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993;28:466-9.
63. Dijkmans, BAC. Folate supplementation and methotrexate. Br J Rhematol 1995;34:1172-4.
64. Hills R, Ive F. Folinic acid rescue used routinely in psoriatic patients with known methotrexate "sensitivity" Acta Derm Venereol (Stockh) 1992;72:438-40.
65. Shupack J, Webster G. Pancytopenia following low-dose oral methotrexate therapy for psoriasis. JAMA 1988;259: 3594-6.
66. Casserly CM, Stange KC, Chren MM. Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis. J Am Acad Dermatol 1993 29:477-80.
67. Evans W, Christensen M. Drug interactions with methotrexate. J Rheumatol 1985;12 (suppl 12):15-20.
68. Thomas DR, Dover JS, Camp RDR. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 1987;17:1055-6.
69. Al-Awadhi A, Dale P, McKendry RJ. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheumatol 1993;20:1121-5.
70. Phillips T, Jones H, Baker H. Pulmonary complications following methotrexate therapy. J Am Acad Dermatol 1987;16:373-5.
71. Filip DJ, Logue GL, Harle TS, et al. Pulmonary and hepatic complications of methotrexate therapy of psoriasis. JAMA 1971216:881-2.
72. Lewis WL, Walter JF. Methotrexate-induced pulmonary fibrosis. Arch Dermatol 1979;115:1169-70.
73. Atkins SA, Byrd JC, Morgan SK, et al. Anaphylactoid reaction to methotrexate. Cancer 1996;77:2123-6.
74. Simmer-Galler I, Lie JY. Choriodal infiltrates as the initial manifestation of lymphoma in rheumatoid arthritis after treatment with low-dose methotrexate. Mayo Clinic Proc 1994;69:258-61.
75. Trenkwalder P, Eisenlohr H, Prechtel K, et al. Three cases of malignant neoplasm, pneumonitis, and pancytopenia during treatment with low-dose methotrexate. Clin Invest 1992;70:951-5.
76. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: Reversible lymphomas associated with Epstein-Barr virus occuring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
77. McKendry RJ, Dale P. Adverse effects of low-dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850-6.
78. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994 73:2759-64.
79. Kozlowski R, van Breda R, Steinbrunner J, et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. J Am Acad Dermatol 1990;88:589-92.
80. Schaff EA, Wortman M, Eisinger SH. Methotrexate and misoprostol when surgical abortion fails. Obstet Gynecol 1996;87:450-2.
81. Hauseknecht RU. Methotrexate and misoprostol for induced abortion. New Engl J Med. 1995.333:537-40.
82. Ayhan A, Ergeneli M, Yuce K, et al. Pregnancy after chemotherapy for trophoblastic disease. J Reprod Med 1990;35:552-4.
83. El-Beheiry A, El-Mansy E, Kamel N, et al. Methotrexate and fertility in men. Arch Androl 1979;3:177-9.
84. Sussman A, Leonard J. Psoriasis, methorrexate and oligospermia. Arch Dermatol 1980;115:215-7.
85. Smith JD, Rnox JM. Psoriasis, methorrexate and tuberculosis. Br J Dermatol 1971;84:590-3.
86. King LE. Complications during methotrexate therapy for psoriasis. Arch Dermatol 1975;111:131.
87. Law KF, Aranda CP, Smith RL, et al. Pulmonary cryptococcosis mimicking methotrexate pneumonias. J Rheumatol 1993;20:872-3.
88. Witty L, Steiner F, Curfman M, et al. Disseminated histoplasmosis in patients receiving low-dose methotrexate therapy for psoriasis. Arch Dermatol 1992;128:91-3.
89. Altz-Smith M, Kendall LGJ, Stamm AM. Cryptococcosis associated with low-dose methotrexate for arthritis. Am J Med 1987;83:179-81.
90. Shiroky JB, Frost A, Skelton JD. Complications of immunosuppression associated with weekly low-dose methotrexate. J Rheumatol 1991;18:1172-5.
91. Wallis PJW, Ryatt KS, Constable TJ. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy. Ann Rheum Dis 1989;48:247-9.
92. Aboguddah A, Stein H, Phillips P, et al. Herpes simplex hepatitis in a patient with psoriatic arthritis taking prednisone and methotrexate: Report and review of the literature. J Rheumatol 1991;18:1406-12.
93. Zonneveld IM, Bakker WK, Dijkstra PF, et al. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Derm 1996; 132:184-7.
94. Kettunen R, Huikuri HV, Oikarinen A, et al. Methotrexate-linked ventricular arrhytmias. Acta Dermato Venereol 1995;75:391-2.
95. Sany J, Anaya J, Canovas F, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993;20:1129-32.
96. Paserchia L, Weisberg J, George D. Methotrexate maylower seizure threshold in patients with epilepsy. J Rheumatol 1992;19:998.
97. Shen DD, Azarnoff DL. Clinical pharmokinetics of methotrexate. Clin Pharmokinet 1978;3:1-13.
98. Cohen MM, Creaven PF, Fossieck BE, et al. Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic cancer. Cancer 1976:38:1556-9.
99. Pinkerton CR, Glasgow JFT, Welshman SG, et al. Can food influence the absortion of methotrexate in children with acute lymphoblastic leukemia Lancet 1980;1:944-6.
100. Mandel M. The synergistic effect of salicylates on mehtotrexate toxicity. Plast Reconstr Surg 1976;57:733-7.
101. Zuik M, Mandel M. Methotrexate-salicylate interaction. A clinical and experimental study. Surgical Forum 1975;26:567-9.
102. Bourke RS, Cheda G, Bremer A, et al. Inhibition of renai tubular transport of methotrexate by probenecid. Cancer Res 1975;35:110-6.
103. Paxton JW. Interaction of probenecid with the protein binding of methotrexate. Pharmacology 1984;28:86-9.
104. Busin K, Escalante A, Beardmore T. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991;18:609-10.
105. Ronchera C, Hernandez T, Peris J, et al. Pharmacokinetics interactions between taking high-dose methotrexate and amoxycillin. Ther Drug Monit 1993;15:375-9.
106. Haim N, Kedar A, Robinson E. Methotrexate-related deaths in patients previously treated with cis-diaminedichloride platinum. Cancer Chemother Pharmacol 1984;13:223-5.
107. Smith CR, Maxwell RR, Edward CQ, et al. Nephrotoxicity induced by gentamycin and amikacin. Johns Hopkins Med J. 1978;142:85-90.
108. Crom WR, Pratt CB, Green AA. The effect of prior cisplatin therapy on the pharmokinetics of high-dose methotrexate. J Clin Oncol 1984;2:655-61.
109. Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring Mates. Ann NY Acad Sci 1971;186:400-22.
110. Bender RA, Bleyer WA, Frisby SA, et al. Alteration of methotrexate in human leukemia cells by other agents. Cancer Res 1975;35:1305-8.
111. Zager R, Frisby S, Oliverio V. The effect of antibiotics and cancer chemotherapeutic agents in the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. Cancer Res 1973;33:1670-6.
112. Covert AJ, Patton S, Fine RL. Pancytopenia from urinary trimethoprim and methotrexate. Ann Intern Med 1992;117:877-8.
113. Maurice M, Davis M, Gall E. Megaloblastic pancytopenia in patient receiving concurrent methotrexate and trimethoprim-sulphamethoxazole. Arthritis Rheum 1986;29:133-5.
114. Ng HWK, Macfarlane AW, Graham RM, et al. Near fatal drug interations with methotrexate given for psoriasis. BMJ 1987;295:752-3.
115. Blackburn W, Alarcon G. Toxic response to topical fluorouracil in two rheumatoid arthritis patients receiving low dose weekly methotrexate: Arthritis Rheum 1990;33:303-4.
116. Daly H, Scott G, Boyle J, et al. Methotrexate toxicity precipitating by azaproprazone. Br J Dermatol 1986;114:733-5.
117. Frenin M, Long K. Methotrexate and non-steroidal anti-inflammatory drug interactions. Ann Pharmacother 1992:26:234-7.
118. Munro RAL, Sturrock RD. Slow-acting antirheumatic drugs: Drug interactions of clinical significance. Drug Saf 1995;13:25-30.
119. Roenigk HH Jr, Auerbach R, Bergfeld WF, et al. A cooperative prospective study of the effects of chemotherapy of psoriasis on liver biopsies. In: Farber EM, Cox AJ, editors. Psoriasis. Proceedings of the Second International Symposium. New York: Yourke Medical Books, 1977:243-8.
120. Ashton RE, Millward-Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982;79:229-32.
121. Lanse SB, Arnold GL, Gowans JDS, et al. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in the treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis: an acceptable risk/benefit ratio. Dig Dis Sei 1985;30:104-9.
122. Robinson JK, Baughman RD, Auerbach R, et al. Methotrexate hepatotoxicity in psoriasis: consideration of liver biopsies at regular intervals. Arch Dermatol 1980;116:413-5.
123. Van de Kerhof PCM, Hoefnagels WHL, Van Haelst UJGM, et al. Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol 1985;10:194-200.
124. Reynolds FS, Lee WM. Hepatotoxicity after long-term methotrexate therapy. South Med J 1986;79:536-9.
125. Zachariae H, Grunnet E, Sogaard H. Liver biopsy in methotrexate-treated psoriatics: a reevaluation. Acta Derm Venereol (Stockh) 1975;55:291-6.
126. Van Dooren-Greebe RJ, Kuijpers AL, Mulder, et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994;130:204-10.
127. Themido R, Loureiro M, Pecegueiro M, et al. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol (Stockh) 1992;72:361-4.